4.3 Article

Muscle dysfunction in axial spondylarthritis: the MyoSpA study

Journal

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Volume 40, Issue 2, Pages 267-273

Publisher

CLINICAL & EXPER RHEUMATOLOGY

Keywords

spondylarthritis; sarcopenia; body composition; muscle strength; physical performance

Categories

Funding

  1. iNOVA4Health
  2. Novartis Portugal
  3. Portuguese Society of Rheumatology

Ask authors/readers for more resources

This study aimed to compare muscle physical properties, strength, mass, physical performance, and the prevalence of sarcopenia between patients with axial spondylarthritis (axSpA) and healthy controls (HC). The results showed that there was no significant difference in muscle physical properties between axSpA patients and HC, despite slightly higher lumbar stiffness. There was also no sarcopenia observed in either group. However, axSpA patients had lower strength and physical performance compared to HC, suggesting possible muscle dysfunction.
Objective We aimed to investigate muscle physical properties, strength, mass, physical performance, and the prevalence of sarcopenia in patients with axial spondylarthritis (axSpA) compared to the healthy controls (HC). Methods We performed a cross-sectional study on 54 participants: 27 patients with axSpA and 27 HC, matched by age, gender, and level of physical activity. Muscle physical properties (stiffness, tone and elasticity), muscle strength (five-times sit-to-stand [5STS] test), muscle mass, physical performance (measured through gait speed) and sarcopenia were compared between the groups. Linear regression models were conducted allowing adjustment for relevant variables. Results Patients with axSpA (mean age 36.5 (SD 7.5) years, 67% males, mean disease duration 6.5 (3.2) years) had no significant difference in segmental muscle stiffness, tone or elasticity, compared with the HC, despite showing a slight numerically higher lower lumbar (L3-L4) stiffness [median 246.5 (IQR 230.5-286.5) vs. 232.5 (211.0-293.5), p=0.38]. No participants presented sarcopenia. Patients with axSpA, compared to the HC, had lower total strength [B=1.88 (95% CI 0.43;3.33)], as well as lower strength in the upper (B=-17.02 (-27.33;-6.70)] and lower limbs [B= -11.14 (-18.25;-4.04)], independently of muscle physical properties. Patients had also significantly lower gait speed than the HC [B= -0.11 (-0.21;-0.01)], adjusted for muscle mass, strength and muscle physical properties. Conclusion Young axSpA patients with a relatively short disease duration presented similar segmental muscle physical properties as the HC and had no sarcopenia. Patients with axSpA had reduced physical performance and lower strength compared to the HC, despite normal muscle mass, suggesting a possible muscle dysfunction. Gait characteristics may be a potential biomarker of interest in axSpA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available